Alethia’s pipeline places great emphasis on the development of monoclonal antibodies generated against its disease-specific targets. AB-16B5, an IgG2 monoclonal antibody for the inhibition of cancer-associated epithelial-to-mesenchymal transition (EMT), is currently under study in animal models of invasive cancers and shows positive pre-clinical results in representative models of prostate and beast cancer. AB-3D3 is lytic IgG1 monoclonal antibody developed against a small cell-surface protein for the treatment of ovarian cancer.
Furthermore, two monoclonal antibody lead candidates are under evaluation as inhibitors of osteoclast differentiation in our severe bone loss programs.
